Nitric oxide synthase (NOS Types I-III) generate nitric oxide (NO), which in turn activates soluble guanylyl cyclase (GC-S). The distribution of this NO-mediated (nitrinergic) signal transduction pathway in the body is unclear. A polyclonal monospecific antibody to rat cerebellum NOS-I and a monoclonal antibody to rat lung GC-S were employed to localize the protein components of this pathway in different rat organs and tissues. We confirmed the localization of NOS-I in neurons of the central and peripheral nervous system, where NO may regulate cerebral blood flow and mediate long-term potentiation. GC-S was located in NOSnegative neurons, indicating that NO acts as an intercellular signal molecule or neurotransmitter. However, NOS-I was not confined to neurons but was widely distributed over
Introduction
The intracellular formation of nitric oxide (NO) has been extensively studied in various mammalian tissues. NO (1, 2) , or a labile intermediate that is able to release NO, is generated from a terminal guanidino nitrogen of L-arginine (3) (4) (5) by a family of NO synthases (NOS; EC 1.14.23) . L-Citrulline is the byproduct of this metabolic pathway. NO is the first messenger molecule of a signal transduction pathway (Figure 1) . Although other targets for NO Supported by research grants DK 30787 and H I . 28474 several non-neural cell types and tissues. These included glia cells, m a d densa of kidney, epithelial cells of lung, uterus, and stomach, and islets of Langerhans. Our findings suggest that NOS-I is the most widely distributed isoform of NOS and, in addition to its neural functions, regulates secretion and non-vascular smooth muscle function. With the exception of bone tissue, NADPH-diaphorase (NADPH-d) activity was generally co-localized with NOS-I immunoreactivity in both neural and non-neural cells, and is a suitable histochemical marker for NOS-I but not a selective neuronal marker. (J Histochem Cytochem 40:1439 -1456 exist (6), its main mechanism of action involves binding to and activation of soluble guanylyl cyclase (GC-S; GTP pyrophosphatelyase (cyclizing), EC 4.6.1.2) (7), which then forms the second messenger molecule guanosine 3',5'-cyclic monophosphate (cGMP).
NOS have been purified and characterized from brain (8) (9) (10) (11) (12) (13) (14) , macrophages (15, 16) , and endothelial cells (17) , and recently also from human cerebellum (18) . Molecular cloning has provided clear evidence that brain (19) and macrophage (20) NOS are products of different genes. The relation between brain and endothelial NOS is unclear. Another polydonal antibody raised against rat brain NOS (21) was reported to bind to endothelial cell matrix, and the authors suggested that brain and endothelial NOS are highly homologous if not identical (22) . Conversely, endothelial NOS was reported by our laboratory to differ from brain NOS with respect to molecular mass and subcellular location (17) and we proposed a classification of at least three types of NOS (Tiable 1) (13).
NOS-I has thus far been detected only in the central and pe- Figure 1 . Protein components of nitrinergic signal transduction. NO Synthase catalyzes the formation of NO from L-arginine. NO in turn activates soluble guanylyl cyclase, which generates the second messenger molecule cGMP NO synthase also has a NADPH-diaphorase activity that is resistant to standard histological fixatives and thus allows the histochemical localization of NOS by formation of nitroblue tetrazolium (NBT) formazan from NET.
ripheral nervous system, whereas functional data suggest that NOS-I is dso present in non-neuronal cells (23-31). Its localization in tissues other than brain is unknown. The main objectives of our study were therefore (a) to develop and characterize a monospecific antibody to rat cerebellum NOS-I, (b) to determine the distribution of NOS-I immunoreactivity in different neural and non-neural cells and tissues of rat, and (c) to compare the localization of NOS-I and GC-S (using antibodies to rat lung GC-S) (32) in adjacent identically prepared tissue sections. NOS-I can also NADPH-dependently reduce nitroblue tetrazolium (NBT) to the water-insoluble dye NBT formazan (NBTF). This so-called NADPH diaphorase (NADPH-d) (33) reaction has been utilized for many years as a histochemical marker activity of neurons (34) and was recently postulated to be due to the presence of NOS-I in histological sections (33,35,36) . We were therefore also interested to compare the localization of NOS-I to that of NADPH-d (using NBTF histochemical staining) in brain and peripheral tissue.
Materials and Methods
Purification of NO Synthases. NOS-I and NOS-I11 were purified from rat cerebellum (13) and bovine cultured aortic endothelial cells (17) as previously described. For immunization of rabbits (see below) NOS-I was rechromatographed by preparative scale SDS-PAGE. A single protein staining band (Coomassie blue) corresponding to NOS-I was excised, destained, and homogenized in 0.5 ml PBS. NOS-I1 (15,32) was partially purified from interferon-y and lipopolysaccharide-induced RAW 264.7 macrophages (American Type Culture Collection; Rockville, MD) as described (13).
F'olydonal Antibody to NOS-I. Female rabbits (6761-6763, New Zealand White, 2 kg) were immunized every 5 weeks with 30 pg purified and rechromatographed (see above) rat cerebellar NOS-I (13). The antigen was emulsified with 0.5 ml complete (first and fourth immunization) or incomplete (all other immunizations) Freund's adjuvant (Difco; Detroit, MI). Serum (5-20 ml) was collected from each rabbit before the first immunization (pre-immune serum, PIS) and 12 days after the first immunization (immune serum 6761-1, 6762-1, 6763-1) and each following immunization (6761-2, etc.) . For immunoprecipitation experiments the immune globulin G (1gG)-containing fractions of three selected immune sera (6761-8, 6762-6, 6763-5) were purified by protein A-Sepharose (Pharmacia LKB; Gaithersburg, MD) chromatography. If not otherwise indicated, experiments were performed with the serum of the eighth post-immune bleed of rabbit 6761 (6761-8) (see Figure I ), which is further referred to as antibody anti-NOS-I.
Monodonal Antibody to GC-S. Monoclonal antibody B4 against the a-subunit (82 KD) (37) of rat lung GC-S was obtained as described (38). It is further referred to as antibody anti-GC-S.
Immunoprecipitation of NOM. Crude supematant fractions of rat brain cytosol or purified NOS-I (see below) were incubated for 60 min at 4% with up to 30 pg purified anti-NOS-I IgG (see above), followed by the addition of protein A-Sepharose 4B beads (Sigma; St Louis, MO). The incubates were then briefly centrifuged (1000 x g, 5 min. 4'C). Supernatant fractions and pellets were assayed for NOS-I activity as determined by activation of GC-S in rat lung fibroblasts (RFL-6; American Type Culture Collection) as described (13.39).
Westem Blot Analysis. Proteinswere fractionated by SDS-PAGE (7.5%), transferred to nitrocellulose membranes (Hybond ECL; Amersham, Arlington Heights, IL), and then air-dried (2 hr). NOS-I was visualized by an indirect immunoperoxidase technique using, unless otherwise indicated, the anti-NOS-I antibody. All following procedures were performed at room temperature as described (28,40). Immune complexes were detected on photographic film by H202 lluminol chemiluminescence (Amersham) and laser-scanned.
Direct and Competition ELISA. ELISA of NOS-I was performed in microtiter plates (Immulon 2 U; Dynatech, Chantilly, VA). Plates were coated For a competition enzyme-linked immunosorbent assay (ELISA) the incubations with anti-NOS antibody were performed in the absence or presence of up to 250 ng purified NOS-I (13) or NOS-I11 (17). respectively.
Histochemistry. Our objective was to demonstrate two immunoreactivities (NOS and GC-S) and one histochemical activity (NADPH-d) in adjacent sections of rat tissues that were prepared by identical procedures. Aldehyde pre-fixation of tissue may result in a morphology superior to that obtained by any other fixation technique and is the method of choice to study the histochemistry of NADPH-d. However. we observed reductions in immunoreactivity of NOS depending on the fixative used. When NOS was coated to microtiter plates, exposed to various fixing solutions, and detected by direct ELISA. acetone had no effect, paraformaldehyde reduced, and glutaraldehyde abolished the immunoreactivity ofNOS (unpublished observation). Moreover, for best results the anti-GC-S antibody is used in unfixed, air-dried cryosections (41). Accordingly, we were forced to choose for all tissue sections the cryosection method followed by a mild acetone fixation. Before initiation of the immunohistochemical experiments, selected tests for nonspecific binding ofconjugate were also performed. Some commercially available anti-rabbit IgG (Kirkegaard & Perry Labs; Gaithersburg. MD) but not others (Sigma; Organon Teknika-Cappel, Durham. NC) bound nonspecifically to endothelial cell matrix. This was independent of preincubation with rabbit anti-NOS-I. A horseradish peroxidase-conjugated anti-rabbit IgG (Sigma) that showed no such phenomenon was therefore chosen for this study to visualize bound anti-NOS-I antibody. With this procedure, sections that were incubated with pre-immune serum instead of anti-NOS-I gave no reaction. A nonspecific immune reaction (independent of primary antibody) was observed in some tissues (e.g.. in uterus) and was due to endogenous peroxidase activity. In detail, tissues were excised from adult Sprague-Dawley rats (200-300 g), frozen in hexaneldry ice. and mounted on microtome chucks using OCT mounting medium (Tissue-Tek; Miles, Elkhart. IN). Sections (8 pm thick) were cut with a cryomicrotome (Frigocut 2800; Reichert-Jung, Heidelberg, Germany), thaw- 
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mounted on microscope slides, fixed by immersion in acetone at 4'C for 5 min, and then air-dried. Slides were stored at 4'C until used. NOS-I and GC-S immunoreactivity was visualized by an indirect immunoperoxidase technique with antibodies anti-NOS-I and anti-GC-S. respectively. All antibodies were diluted in PBS containing 1% BSA. Slides were preincubated in PBS for 5 min followed by: anti-NOS-I or anti-GC-S (1:IOO or 1300, 30 min. 37°C); PBS wash ( 5 min. twice); peroxidase-conjugated, affinity-purified polyclonal goat antibody to rabbit IgG or mouse IgG. respectively (1:300; 30 min at 37'C); PBS wash ( 5 min, twice); and TBS wash (10 min). The peroxidase label was developed with DAB and 0.005% H202 dissolved in imidazole buffer (pH 7.6.6-10 min). Slides were finally washed in TBS, dehydrated in a graded series of ethyl alcohols. and mounted with resin (Tissue-Tek) and class coverslips.
For histochemical staining of NADPH-d (NBT formazan formation), slides were immersed for 20-30 min at 37°C in 50 mM TBS (pH 8.0) containing 1 mM NADPH. 0.5 mM NBT, 0.2% Triton X-100. washed briefly in PBS. in some cases counterstained with eosin, dehydrated, and mounted as described. NBT formazan formation was NADPH dependent and was not affected by superoxide dismutase (SOD).
Preparation of Crude Supernatant and Particulate Fractions. Organs from adult Sprague-Dawley rats (200-300 g) or pelleted tissue culture cells were homogenized in 5 volumes (according to wet weight in g) of ice-cold Buffer 1 (see above) by means of a Polytron and teflon-glass grinder. Each homogenate was centrifuged at 105,000 x g (YC, 1.5 hr). resulting in a clear supernatant fraction, which was stored at -70°C in the presence of glycerol (10%. vlv).
Other Assays. NOS activity, i.e., citrulline formation (13.42). or cGMP increase in RFL6 cells (39). and NADPH-d activity (14,33,40) was determined as described. Protein concentrations were determined according to Bradford (43) with BSA as a standard.
Characterization of the Anti-NOS-I Antibody
In Western blot analysis, sera of three different rabbits which had been immunized with purified rat cerebellar NOS-I (160 KD) bound avidly to a single 160 KD protein band in rat cerebellar 105.000 x g supernatant fractions ( uterus also contained a single crossreacting protein band, which varied in molecular mass between 150-165 KD and was broader than in brain tissues. In all tissues, the relative intensity of this band coincided with NOS-I activity, i.e., Ca2+-dependent, NG-methyl-L-arginine (MeArg)-inhibitable citrulline formation, and NADPH-d activity, i.e. NADPH-dependent, superoxide-independent NBT formazan formation ( Figure 3C ). The lowest specific NOS activities were found in lung, uterus, and kidney, which were subsequently shown to contain NOS-I immunoreactivity in their epithelial cell layers (see below). The apparent detection limit for NOS-I in Western blot analysis was <lo pg with anti-NOS-I at a 1:4000 dilution. The highest anti-NOS-I titer in a direct ELISA with 25 ng purified NOS-I was 1:30,000. All antisera also immunoprecipitated purified NOS-I ( Figure 3A ). NOS-I activity was completely recovered in the immunoprecipitate when antisera 6762-6 and 6763-5 were used and only partially with anti-NOS-I. As shown for anti-NOS-I, none of the antisera crossreacted with NOS-I1 and NOS-111, either in a competition ELISA ( Figure 3B ) or in a Western blot (Figure 4) .
Histology in the Nervous System
The antibodies anti-NOS-I and anti-GC-S (38,41) were chosen to localize NOS and GC-S immunoreactivity, respectively, in various rat tissues. In addition, NADPH-d activity was analyzed as a potential histochemical marker technique for NOS-I. In several tissues, the results with anti-NOS-I were confirmed by use of antiserum The location of white matter (wm), cerebellar cortex (ct), Purkinje cell layer (pu). basket cells (ba), granular (gl). and molecular (ml) layer is indicated. Bars: A,B = 1 mm; C.D = 0.2 mm; E,F = 0.1 mm.
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. . . 6763-5 (data not shown). In all tissues, the specificity of the immunodetection was wrified by absence of staining with pre-immune sera (see below). In the brain, most NOS-I immunoreactivity was confined to the cerebellar cortex (Figure 5 ) , confirming the distribution of apparent NOS-I activity in various rat brain regions (44). The most intense staining for NOS was observed in cells that make close contact with Purkinje cells, i.e., in basket and granular cells, and, although weaker, also in Bergmann glia and astrocytes. In the molecular and granular layer, other neural cells, neuropil (dendrites, axon terminals), and glial processes were also stained. The distribution of NADPH-d activity paralleled the staining pattern for cr F c>r 1 mu mm . NOS-I in the cerebellum (data not shown). The white matter was free of staining except for a few single cells, possibly neurons, which also stained positively for NADPH-d activity. Neurons that clearly contained neither NOS-I nor NADPH-d were Purkinje cells. These cells, however, were the predominant cell type within the cerebellum that stained positive for GC-S. A very faint GC-S immunoreactivity was also noted for fibers and cell bodies of Bergmann glia and other small cells in the granular and molecular layer. In the olfactory bulb ( Figure 6 ), a similar distribution was found. NOS-I and NADPH-d were co-localized in the same cell layer, whereas GC-S was located in an adjacent, more peripheral layer of oligodendrocytes in the adjacent internal granular layer. In the hippocampal formation (Figure 7) , staining for NOS-I, NADPH-d. and GC-S was observed in the corpus ammonis and in the granular cell SCHMIDT, GAGNE. NAKANE, POLLOCK, MILLER, MURAD layer of the dentate gyrus. In the corpus ammonis, most of the NADPH-d-and NOS-I-positive neurons were outside the pyramidal cell layer; however, some of the pyramidal cells and their apical dendrites were NOS-I positive, whereas all were GC-S positive. Staining was also observed in the entire periphery of the posterior and anterior colliculi, the striatum (data not shown), and posterior thalamic nuclei (perifascicular). In the pituitary ( Figure 6 ). very intense staining for NOS-I and NADPH-d was observed in nerve terminals of the pars nervosa and in the epithelial remnants of Rathke's pouch, which separates the pars intermedia and pars anterior of the pituitary.
In the peripheral nervous system of the rat, including single peripheral nerve fibers, entire nerve bundles, and ganglia, strong NOS-I immunoreactivity and NADPH-d activity were observed. NOS-I and NADPH-d were again co-localized, as shown for heart ( Figure 8 ), pancreatic ~s c u l a r bundles (Figure 9 , anococcygeus muscle, and duodenum ( Figure 8 ).
pancreas (Figure lo) , lung and kidney (Figure 11) , and uterus and stomach (Figure 12 ). Again. NADPH-d was co-localized with NOS-I. In pancreas the islets of Langerhans were stained, whereas exocrine cells showed no staining. In other tissues, epithelial cell layers were specifically stained, i.e., in lung, the terminal and respiratory bronchioli, including mucosal foldings, but not alveolar ducts or larger bronchi, stained; in the kidney, dense staining of macula densa cells for both NOS-I and NADPH-d occurred and
Histology in Non-neural Cells ana' Tissues
In addition to the brain and peripheral nervous system, several nonneural cell types that stained positive for NOS-I were detected in a weaker staining of other tubular epithelial cells for NADPH-d took place; in uterus, a similar staining of columnar epithelium of the endometrium was observed; and in the forestomach the gastric mucosa stained. Bone tissue represented one exception to the generally observed co-localization of NOS-I and NADPH-d. In longitudinal sections of femur, no NOS-I immunoreactivity (data not shown) but strong NADPH-d activity ( Figure 13) was observed in the zones of chondrocytes and ossification, including the entire osteoclastic-osteoblastic cell layer.
Endothelial cells of various peripheral blood vessels (pancreas, kidney, lung) or large conducting blood vessels (abdominal aorta, vena cava), endocardial cells, and smooth or cardiac muscle cells did not contain NOS-I immunoreactivity.
The staining for GC-S was ubiquitous in all tissues studied, with slightly higher immunoreactivity in lung and weak immunoreactivity in kidney (data not shown).
Discussion
Polyclonal antibodies to rat cerebellum NOS-I were generated in rabbits. The obtained immune sera recognized NOS-I and a single protein band in crude cytosol of brain and several peripheral tissues. The mass of this band varied between 150-165 KD, possibly indicating partial proteolysis during preparation and/or multiple post-translational modifications. In two assay systems none of the immune sera crossreacted with purified endothelial NOS. This observation further supports our view that endothelial and brain NOS are structurally different proteins (Tkble 1). Recently, molecular cloning of a cDNA encoding NOS-I11 from a bovine aortic endothelial cell library revealed a 60% amino acid identity (45), providing additional support for our classification of NOS. Macrophage NOS-I1 is also not recognized by anti-NOS-I. Moreover, immunological stimulation of cells is required for them to express NOS-11. In tissues of normal rats, NOS-I1 is therefore, not likely to be present. In conclusion, the anti-NOS antibody that was used in this study was monospecific and suitable to specifically map the distribution of NOS-I in the rat.
No Co-localization of NOS-I and GC-S
In brain, NOS-I and GC-S were generally not co-localized. As shown for cerebellum and olfactory bulb, NOS-I and its target enzyme GC-S were often located in adjacent cells or cell layers. NO therefore appears to act as an intercellular messenger or niuinergic neurotransmitter. GC-S immunoreactivity was diffuse in lung and smooth muscle, and weak or absent in kidney, allowing no clear statement on the morphological relation between NOS-I and GC-S in peripheral organs.
The histological localization of guanylyl cyclases has previously been extrapolated from the location of their enzymatic product, cGMP (46), or from the location of cGMP-dependent protein kinase (PKG) (21, 22) . Their distribution appeared to match that of GC-S, with the exception of Purkinje cells in the cerebellum, which are immunoreactive for GC-S and PKG (47) but not for cGMP (46). However, the detection of cGMP immunoreactivity greatly depends on the effective blockade of cGMP-phosphodiesterase activity and is impeded by the high solubility of cGMP in water. PKG may not always be the target enzyme for cGMP and will therefore not necessarily follow the distribution of GC-S. Consequently, both markers (cGMP and PKG immunoreactivity) cannot substitute for the detection of GC-S. Due to the present lack of a GC-S-common antibody, even the immunocytochemical detection of GC-S is not applicable to every tissue. GC-S is a heterodimer (37) of one aand one 0-subunit. The anti-GC-S antibody used in the present study was generated against purified rat lung GC-S and recognizes the a-subunit of GC-S. Molecular cloning techniques have recently revealed that at least two isoforms of each GC-S subunit exist: a1 (78 KD), a2 (82 KD), 01 (70 KD), PZ (76 KD) (48, 49) . How many aand 0-subunits exist in the GC-S gene family is uncertain. The distribution of each subunit may also vary between different tissues. Kidney, for example, may contain a GC-S that is immunologically distinct from the alp1 isoform of lung GC-S (48).
Co-localization of NOS-I and NADPH-d in Brain
In brain, immunoreactivity for NOS-I was most intense in cerebellum, hippocampus proper, and olfactory bulb. Spinal cord was not investigated. NADPH-d activity closely paralleled NOS-I immunoreactivity. The situation may be different in rats that are in an immunologically activated state and express NOS-11. However, in the normal rat both techniques, NOS-I immunocytochemistry and NADPH-d cytochemistry, are suitable to study the distribution of NOS-I. The sites of NO biosynthesis in the brain appeared to be both neuronal and non-neuronal (see below). Among the neurons that were clearly identified was a subpopulation of hippocampal pyramidal cells and the perifascicular thalamic nucleus.
The so called NO hypothesis in the brain (50) suggests that NO functions as a retrograde messenger in synaptic plasticity phenomena such as long-term depression in the cerebellum (51) and long-term potentiation in the hippocampus (52). A localization of NOS-I in postsynaptic neurons, e.g., pyramidal cells, adds support to this hypothesis.
Neural NO would also be ideally suited as a mediator coupling cerebral blood flow to neural activity (50). The observation that NOS-I was located in the perifascicular thalamic nucleus, a region of the brain that when activated by microstimulation increases cerebral blood flow (53), suggests that NOS has, indeed, a key role in cerebral blood flow regulation. Further evidence supporting this view can be extrapolated from functional studies which show that arginine analogues which inhibit NOS-I activity (NOS inhibitors) also decrease cerebral blood flow (54). In particular, activation of the basal forebrain elicits remarkable increases in cortical cerebral blood flow independent of cortical cerebral glucose utilization (55,56); this effect is enhanced by L-arginine and blocked by NOS inhibitors (57) .
NO might also have pathophysiological significance in the CNS (54), e.g., in disease states such as migraine and seizures. NO (and L-arginine) were shown to be the mediators of (or required for) glutamate-induced neurotoxicity (58) and to have proconvulsant effects. Excessive NO production may contribute to the development of epileptic foci (59). Since NOS-I with a molecular mass and biochemical characteristics identical to rat brain NOS-I has been described in human brain (18), nitrinergic signal transduction in the CNS and its pathophysiological implications are of relevance for human medicine.
Peripheral Nitrinergzc Nerves
There is considerable evidence that the PNS of the entire gastrointestinal (GI) tract [esophagus (60,61) , stomach (24) , duodenum (62), ileum (63), ileocolonic junction (64), colon (65)] and of other smooth muscle tissues [corpus cavernosum (66) and urethra (67)] contains non-adrenergic, non-cholinergic nerves (NANC). The fact that NOS-I is located in the NANC nerves of these tissues justifies the novel term of nitrinergic nerves (the terms nitroxergic and nitrergic have also been used).
Moreover, in many other organs almost all neurovascular bundles and several nerve fibers were found to contain NOS-I immunoreactivity, suggesting that nitrinergic nerves are as widespread as are adrenergic and cholinergic nerves. It is conceivable that nitrinergic nerves represent a third nervous system. However, NO may be released either postsynaptically or presynaptically, possibly together with other neurotransmitters, to modulate the release or function of acetylcholine (68) or norepinephrine (69).
Cardiac nitrinergic nerves but not cardiac muscle stained positive for NOS-I or NADPH-d. The reported release of NO from perfused heart (70) is therefore likely due either to an endocardial NOS distinct from NOS-I, e.g., NOS-111, or to NOS-I of cardiac nitrinergic nerves. Whichever is the source of endogenous NO in the heart, under certain conditions NO will be of physiological importance, as indicated by the cardiodepressant effects of NOS inhibitors (71).
CO-localization of NADPH-d and NOS in Non-neural Cells
Brain. NADPH-d activity is considered to be a neural marker and its co-localization with NOS-I in brain is regarded as evidence that, at least in brain, NOS-I is expressed only in neurons (21,36). However, the majority of the neuropil and cells that stained positive for NOS-I and NADPH-d in the vicinity of Purkinje cells also included astroglia. Although electron microscopic analysis will be required to definitively answer this question, our data suggest that glia expresses NOS-I. Furthermore, astroglial localization of GC-S (72) and NOS-I activity in cultured astrocytes (23, 73) has already been demonstrated by immunohistochemistry and NO-mediated increases in cGMP levels of astrocytes, respectively.
Epithelial Cells. Although our results support a role of NOS-I in neurotransmission, they also suggest novel para-neuronal roles for NOS-I and nitrinergic signal transduction in epithelial andlor secretory cells of lung, uterus, kidney, stomach, pancreas, and pituitary. These cells have thus far not consistently been reported to form and release NO.
In the lung, NOS-I was located in the secondary and terminal bronchioli but not in the alveoli and large bronchi. Lung contains NOS-I activity (74) and airway smooth muscle responsiveness is regulated by the bronchial epithelium (75). The fact that inhaled NO is an effective therapeutic agent in pulmonary hypertension (76) and the adult respiratory distress syndrome (77) suggests that endogenous bronchiolar epithelium-derived NO may have impor-tant functions in the regulation of vascular and non-vascular smooth muscle.
The location of NOS-I in the small and specialized tubular epithelial cell population of macula densa supports and extends a previous report which showed that the kidney epithelial cell line LLC-PKl(78) contains a functional nitrinergic signal transduction pathway. The macula densa mediates the tubuloglomerular feedback by which the kidney adjusts the glomerular filtration rate to tubular flow and reabsorption rates. The kidney microcirculation was recently shown to be impaired by @-monomethyl-Larginine (MeArg), an inhibitor of NOS (79, 80) . MeArg also affects glomerular capillary pressure, which effect is dependent on macula densa function (unpublished observation). Functional studies under various conditions, i.e., low and high salt intake, and in various animal models of arterial hypertension will now be of great interest.
Compared with other segments of the GI tract, the specific NOS-I activity in stomach is exceptionally high (81). Functional experiments indicate that gastric NOS-I is located in nitrinergic nerves, mediating reflex relaxation of the stomach to accommodate food or fluid (24) . However, the potent gastroprotective effects of exogenous and endogenous NO (25-27) suggest an additional epithelial location of NOS. Our data clearly establish such a localization of NOS (and NADPH-d) in the epithelium of the gastric mucosa. In this context, it is interesting that GI epithelial cells (enterocytes) are NADPH dependent in the conversion of L-arginine to L-citrulline (82) and that nutrients such as glucose appear to induce NO release in these cells (83) . Owing to the acidic conditions in the gastric lumen, NO once released will have an extremely long half-life and may therefore reach concentrations that exert both regulatory and mutagenic (84) or toxic (85) effects in the stomach. In other tissues, the toxic effects of NO are likely to occur only after induction of NOS-I1 expression. It is therefore intriguing to speculate on a role of endogenous NO in the pathogenesis of gastric ulcer and cancer. Interestingly, cyclic GMP levels are elevated in neoplasms, proliferating tissues, and associated disease states (86) (87) (88) (89) .
NOS-I and NADPH-d were also highly concentrated in the epithelium of endometrium. The role of NO in uterine function has not been investigated. However, 17P-estradiol stimulates cGMP accumulation in the uterus (90) , which in tum up-regulates estradiol binding sites in the cytosol of endometrial cells (91, 92) . Cyclic GMP levels are at their highest in pro-estrus (93) , when the concentration of total uterine receptors is reported to be maximal (94) . Furthermore, cGMP was suggested to be a mediator of the estrogenstimulated rapid uterine secretory response (95) , is increased in the implantation site (96) , and inhibits uterine oxytocinase, possibly augmenting oxytocin's effects in parturition (97) . It remains to be established whether changes in uterine cGMP levels are subject to regulation by endogenous NO. Secretory Cells. NO is also likely to be involved in the regulation of stimulus-secretion coupling. In the pancreas, NOS-I was colocalized with NADPH-d in the islets of Langerhans. Functional studies have demonstrated NO release (28) and NO-related electron paramagnetic resonance signals (98) in pancreatic B-cells and isolated islets of Langerhans, respectively. Furthermore, Larginine and D-glucose induce the release of NO, an increase in cGMP levels, and the release of insulin from pancreatic B-cells (28, 29) . The fact that MeArg inhibits D-glucose-induced insulin release (28) (29) (30) indicates that insulin release is, in part, caused by or dependent on nitrinergic signal transduction. The presence of NOS-containing nerves and ganglia in the pancreas has also been observed U. Po-l&, personal communication). Therefore, neuronally released NO may also participate in the regulation of insulin secretion. Similar to the situation in the CNS and stomach, NO can also have adverse effects in the pancreas. Interleukin-10 (IL.10) can induce an NOS (probably NOS-11) in resident or infiltrating macrophages of islets of Langerhans, resulting in B-cell destruction (30,98) , which mechanism may be essential in the pathogenesis of insulin-dependent diabetes mellitus.
Another tissue in which NO is likely to have regulatory functions in peptide hormone release is the pituitary gland. NOS-I and NADPH-d were co-localized in the posterior pituitary, which suggests a role for NO in oxytocin or vasopressin release. The pars anterior showed weaker staining for NOS-I. L-Arginine has been shown to stimulate growth hormone release (99) , but this effect may not be due to L-arginine-derived NO formed in the pituitary. Alternatively, L-arginine may affect growth hormone release indirectly by suppressing endogenous somatostatin secretion (100).
Although NOS-I in the endometrium, stomach, and bronchioli may regulate smooth muscle function, an additional function of NO in these tissues may be to regulate the secretion of cytotoxic hydrochloric acid (stomach) or cytoprotective mucous (stomach and bronchioli).
Bone
Despite the absence of NOS-I immunoreactivity in rat bone, NADPH-d activity was strong, suggesting that osteoclasts and/or osteoblasts contain NOS-I1 or, more likely, NOS-111. Our finding may represent the first histological description of NOS in bone tissue, where osteoclastic inhibition by NO has been shown (31).
In conclusion, our data demonstrate that in various neural and non-neural cells NOS-I is frequently co-localized with NADPH-d but not with GC-S, NO can therefore act as an intercellular messenger. In the central and possibly the peripheral nervous system, NO functions as a novel widespread nitrinergic neurotransmitter. The localization of NOS-I and NADPH-d in epithelial and/or secretory cells suggests novel para-neural functions for NO in cell communication and signal transduction, i.e., in epithelial regulation of smooth muscle function and stimulus-secretion coupling. 
